Dupilumab Shows Promise for a Tough-to-Treat Sinus Condition: Chronic rhinosinusitis without nasal polyps (CRSsNP)

Chronic rhinosinusitis without nasal polyps (CRSsNP) can be frustrating - persistent sinus inflammation, congestion, and often a damaged sense of smell, but without the polyps that make some cases easier to target with existing biologics. For the eosinophilic subtype (driven by high levels of eosinophils), standard treatments frequently fall short.

A new small but intriguing randomized, double-blind, placebo-controlled trial offers hope. Researchers tested dupilumab - the IL-4/IL-13 inhibitor already FDA-approved for chronic rhinosinusitis with nasal polyps - in patients with eosinophilic CRSsNP.

In just 13 participants (10 on dupilumab, 3 on placebo), after 24 weeks:

Sinus CT scans improved markedly in the dupilumab group (a 5.38-point better Lund-Mackay score, statistically significant with p=0.023).

Sense of smell recovered substantially (about 11 points better on the UPSIT smell test, p=0.045).

Subjective symptom scores didn't differ significantly, and while inflammatory biomarkers trended downward, they weren't statistically significant in this tiny sample.

Bottom line: These early results suggest dupilumab could reduce objective sinus disease and restore smell in eosinophilic CRSsNP - a meaningful win for a condition with few good options. Larger trials will be essential to confirm efficacy, safety, and who benefits most, but this pilot study opens an exciting door for biologic therapy in non-polyp sinus disease. Stay tuned for bigger studies!

References:

https://www.sciencedirect.com/science/article/pii/S0091674925021505